# Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

> **NCT02175121** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 172 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06291874
- **DRUG:** PF-06291874
- **DRUG:** PF-06291874
- **DRUG:** PF-06291874

## Key facts

- **NCT ID:** NCT02175121
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2016-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175121, "Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02175121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*